COVID-19 Proteins and Others

COVID-19 is one of most severe and contagious virus in human history. Based on its strong scientific capacities, Biortus had heavily involved in COVID-19 pathological and drug development studies from the very beginning. Biortus Protein Production Department produced the RdRp enzyme, and Assay & Screening Department studied the inhibitory mechanism of remdesivir developed by Gilead. More recently, Biortus CryoEM Department studied RdRp interaction with compound AT-520, and identified multiple binding sites. The novel discovery suggests that RdRp inhibitor could play more roles than RNA chain termination.